Article Text

PDF
Extended report
The prevalence of inflammatory back pain: population-based estimates from the US National Health and Nutrition Examination Survey, 2009–10
  1. Michael H Weisman1,
  2. James P Witter2,
  3. John D Reveille3
  1. 1Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, California, USA
  2. 2Rheumatic Diseases Clinical Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA
  3. 3Division of Rheumatology, University Texas, Houston, Texas, USA
  1. Correspondence to Michael H Weisman, Cedars-Sinai Medical Center, Division of Rheumatology, Los Angeles, California 3556, USA; michael.weisman{at}cshs.org

Abstract

Objective To estimate the current US inflammatory back pain (IBP) prevalence using four published case definitions.

Methods Analysis of an IBP data collection instrument specifically designed for the 2009–10 National Health and Nutrition Examination Survey. Subjects were 5103 US adults ages 20–69 with complete data. IBP prevalence as determined by Calin et al criteria, European Spondylarthropathy Study Group (ESSG) criteria, and Berlin criteria 8a and 7b.

Results Age-adjusted US prevalence of IBP by Calin criteria was 5.0% (95% CI 4.2% to 5.8%). Prevalence of IBP was 5.6% (95% CI 4.7% to 6.5%) by ESSG criteria, and 5.8% (95% CI 5.2% to 6.4%) and 6.0% (95% CI 4.9% to 7.1%) by Berlin Criteria 8a and 7b, respectively. IBP prevalence did not differ significantly by age groups or between men and women. IBP prevalence was significantly lower among non-Hispanic black persons compared with non-Hispanic white persons for the Calin and ESSG IBP criteria. For the ESSG and Berlin 7b criteria, non-Hispanic white persons had significantly higher IBP prevalences compared with Mexican Americans.

Conclusions IBP is associated with spondyloarthritis. Awareness of the prevalence of IBP may be useful for planning future epidemiological studies as well as development and validation of diagnostic and classification criteria for specific clinically defined diseases.

Statistics from Altmetric.com

Footnotes

  • Funding An unrestricted grant to the CDC Foundation from the SAA and SPARTAN.

  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.